Highlights of regional meeting of Italian Southern Oncological Group (GOIM): Focus on hepatocellular carcinoma: Biological and clinical background, therapeutic guide-lines and perspectives

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 373-378

  Addeo, Raffaele ^a   Caraglia, Michele ^b   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bevacizumab; Combination therapy; Hepatocellular carcinoma; Octreotide; Sorafenib; Target based agents

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; ALCOHOL; ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMMUNOMODULATING AGENT; LAPATINIB; LONG ACTING DRUG; MITOXANTRONE; OCTREOTIDE; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; THYMOPHYSIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VATALANIB; ANTINEOPLASTIC AGENT;

CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC RISK; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRACTICE GUIDELINE; QUALITY OF LIFE; SIGNAL TRANSDUCTION; LIVER TUMOR; METABOLISM; MULTIMODALITY CANCER THERAPY; ONCOLOGY; TIME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; ITALY; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS;

EID: 67449104619     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802680158     Document Type: Conference Paper

References (12)

1. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14(11):1652-6 • This manuscript describes the epidemiology of HCC and its association with well known risk factors.
2. Lau WY. A review on the operative techniques in liver resection. Chin Med J 1997;110:567-570 (Pubitemid 127510193)
3. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 (Pubitemid 34607087)
4. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-81 •• This manuscripts describes the first study, to our knowledge, demonstrating somplete remission in HCC achieved through the use of a a combination chemotheraphy schedule. However, the study demonstrates also that this regimen is poorly manageable and induces severe toxicity in this subset of patients, often characterized by co-morbidities.
5. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406 (Pubitemid 44142735)
6. Caraglia M, Tassone P, Marra M, et al. Targeting raf-kinase: molecular rationales and translational issues. Ann Oncol. 2006;17 Suppl 7:vii, 124-7 • This manuscript is a general overview about raf kinase as a target for anti-cancer therapy discussing new scenarios of intervention based upon raf kinase inhibition.
7. Llovet J, Mazzaferro V, Ricci S, et al. Sorafenib improves survival in a large multi-center, randomized, placebo-controlled Phase III trial in patients with hepatocellular carcinoma [Abstract #3507]. Presented at: ECCO 23-27 September 2007; Barcelona, Spain. Eur J Cancer Suppl 2007;5:261
8. Cheng A, Kang Y, Chen Z, et al. Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [Abstract 4509]. J Clin Oncol 2008;26(Suppl)
9. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafinib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis [Abstract 140]? Gastrointestinal Cancers Symposium ASCO; 2008
10. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48 (4):1312-27 •• This manuscript describes the most important clinical trials performed with target-based agents alone or in combination with cytotoxic drugs on HCC paptients.
11. Deli A, Kreidl E, Santifaller S, et al. Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 2008;14:1699-1709
12. Abou-alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 2008;10:199-205